This article is referred to in the Editorial by X.-J. Du diovascular disease in postmenopausal women, although ( pages 4 -7) in this issue.
the data are controversial and the final causative mechanism remains unclear [4, 5] . Traditionally, the major mechanisms responsible for the protective effect of female 1 . Introduction gender is believed to be due to an antiatherogenic action of estrogen on the lipid profile. More recently Ranki and Death from cardiovascular disease is relatively lower in co-workers [6, 8] and Jovanovic et al. [7] have demonpremenopausal women compared with age-matched men strated that estrogens protects cardiac cells to metabolic [1] . However, after menopause, the risk of coronary heart injury in a gender and ageing-specific manner. However, disease increases dramatically [2, 3] . Several reports have new data suggest that estrogen may also exert its beneficial suggested that hormone replacement therapy reduces careffects though a direct action on the vascular wall (for review, see Ref. [9] ).
At present, there are two estrogen receptors (ER), about the type of ER expressed in human neutrophils. In identified ERa and ERb, both of which are members of the this regard, although a great deal of progress has been superfamily of steroid hormone receptors. ERa and ERb made in cloning ER subtypes, very little is known about have considerable homology and, like all steroid hormone control of the expression of the ER subtypes. In this sense, receptors, are transcription factors that alter gene expresestrogen itself has been demonstrated to upregulate ER sion when they are activated. Both ER form homodimers expression in neonatal rats, ovine uterine cells and ewes and may form heterodimers with each other, which have endometrium and downregulate them in ewes liver and been shown to be active in experimental systems [10] .
MCF-7 breast cancer cells under conditions of limited cell In spite of the growing interest in the action of estrogen growth [14] [15] [16] [17] [18] . However, to date it is not known if on the endothelium less is known about the effect of estrogen regulates ER expression in human neutrophils. estrogen on other cells activated in cardiovascular diseases Therefore, the aims of the present study were (a) to such as neutrophils. Binding studies performed by identify the different ER subtypes expressed in neutrophils Klebanoff [11] demonstrated the presence of ER on from premenopausal women and from healthy men, (b) to neutrophils. Moreover, we recently demonstrated that 17b-determine the involvement of estrogen in the regulation of estradiol stimulated the expression of the neuronal nitric their own ER, and (c) to analyze the association between oxide synthase isoform (nNOS) in human neutrophils by the modifications in the expression of ER subtypes and an ER-dependent mechanism [12] . The increased expresnNOS expression induced by estrogen. sion of nNOS induced by 17b-estradiol in human neutroThe molecular mechanism by which nuclear receptors phils was associated with a reduction in their adhesive modulate gene transcription has, in its simplest form, properties and favoured the antiplatelet effect of neutroinvolved the binding of the ER to an estrogen responsive phils [12, 13] . However, at present there are no evidences element (ERE) within the promoter of target cells. How- ever, there are genes that do not contain a canonical ERE, were obtained from the same donor (n510) at two including the 59-flanking region of nNOS gene [19] . different points: (1) the ovulatory phase identified by the However, ER may form complexes with transcription urinary peak of luteinizing hormone (LH) (by disposable factors such as Sp-1 and AP-1. Thus, the cooperative test sticks (Donnatest Wyntek Diagnostic, San Diego, CA)) interaction of Sp-1 and AP-1 with ER proteins regulate and (2) within the first 2 days of the follicular phase several estrogen-inducible genes [20] [21] [22] 
.2. Neutrophils obtained from premenopausal women
To determine the in vivo effect of estrogen, neutrophils represented as mean6S.E.M. of ten different experiments. * P,0.05 with P,0.05 with respect to 17b-estradiol in the presence of ICI 182780.
respect to neutrophils in the absence of 17b-estradiol.
women during follicular phase were incubated with 17b-each donor as an independent experiment. 10% polyacrylamide gels (15 mg / lane) as previously ml (5.9310 mol / l). Analysis of ER receptors using the described [26, 27] . To verify that equal amounts of proteins polyclonal antibody MC-20 that recognizes both a and b had been loaded in the gel, we run and stained a parallel ER subtypes showed an increased expression of ER in the gel with identical samples with Coomassie to compare the intensities of the protein bands. ER protein expression was determined using the polyclonal antibody MC-20 (Santa Cruz Biotechnology, Santa Cruz, CA). This antibody recognizes a common sequence of a and b ER subtypes [28] . The expression of a and b RE subtypes was further identified by specific monoclonal antibodies against each receptor (Santa Cruz Biotechnology). nNOS determination was also performed by Western blot as previously reported [12,26,27].
.5. Electrophoretic mobility-shift assay
Nuclear protein extracts were prepared from neutrophils incubated for 30 min in the presence and in the absence of 28 17b-estradiol (10 mol / l). Nuclear proteins were then mixed with an oligonucleotide corresponding to doublestranded Sp1 or AP1 consensus oligonucleotide (59-ATT CGA TCG GGG GGG GGC GAG C-39 for Sp1 and 59-CGC TTG ATG AGT CAG CCG GAA-39 for AP1, Promega). Each oligonucleotide was end-labelled using 32 [g-P]ATP and T polynucleotide kinase. Standard bind- 4 ing reactions were performed by incubating 10 mg of nuclear extracts in 20 ml of 10 mmol / l Tris-HCl, pH 7,5, containing 100 mmol / l NaCl, 1 mmol / l dithiothreitol, 1 mmol / l EDTA, 10 mmol / l MgCl , 20% (v / v) glycerol, 2 32 and 50 000 dpm of P-labelled Sp1 or AP1 oligonucleotides (approximately 1 pmol), for 20 min at room temperature, as reported [29] . After incubation, the samples were loaded onto a 4% polyacrylamide gel and run at a constant current of 100 V in 0.53 Tris-borate-EDTA (TBE) at 4 8C, as described [29, 30] . Gels were dried and placed on film at 270 8C. neutrophils obtained during the ovulatory phase compared was observed by Western blotting using the MC-20 with those found in the follicular phase (Fig. 1A) . No polyclonal antibody (Fig. 2) and incubation of neutrophils 28 changes in the expression of b-actin protein were observed derived from men with 17b-estradiol (10 mol / l) en-
28
in neutrophils from the follicular and ovulatory phases hanced the expression of ER (Fig. 2) . 17b-estradiol (10 (Fig. 1A) . Then, we analyzed the expression of each ER mol / l) failed to modify b-actin expression in neutrophils 28 subtype expressed in the neutrophils from premenopausal derived from men (Fig. 2) . The dose of 10 mol / l 17-b women in the two phases of the menstrual cycle using estradiol was chosen based in previous studies in which we specific monoclonal antibodies against ERa and ERb, have demonstrated that this dose of 17b-estradiol increased respectively. Neutrophils obtained during the ovulatory nNOS protein expression in human neutrophils [12, 13] . phase showed a higher expression of both ERa and ERb
We further determined whether estrogen regulate the subtypes than neutrophils obtained during the follicular expression of their own receptors. For this purpose, ERa phase (Fig. 1B) Both tamoxifen (10 mol / l) and ICI 182780 (10 28 mol / l) reduced the expression of ER induced by 10 mol / l 17-b estradiol in neutrophils derived from men, suggesting the involvement of estrogen in the autoregulation of ER in neutrophils (Fig. 2) . The ER antagonists were added 10 min before 17-b estradiol. The reduction in
ER expression achieved with 10 mol / l ICI 182780 was 28 of higher magnitude than that obtained with 10 mol / l tamoxifen (Fig. 2) . Under basal conditions, neither ICI 28 28 182780 (10 mol / l) nor tamoxifen (10 mol / l) modified ER expression in neutrophils (Fig. 2) . Western blot analysis of the ER subtype expressed in neutrophils derived from men showed that, as occurred in neutrophils from premenopausal women, both ERa and ERb subtypes were expressed (Fig. 3A and B) . However, only the expression of the ERa subtype was enhanced by 28 28 10 mol / l 17b-estradiol (Fig. 3A) . ICI 182780 (10 mol / l) almost completely inhibited the enhanced expression of ERa subtype induced by 17b-estradiol (Fig. 3A) . Therefore, to analyze whether the different ER expression upregulated the expression of both ERa subtypes and ERb in neutrophils from women and men was due to gender subtype in neutrophils isolated from women ( Fig. 4A and differences or to the in vivo and in vitro condition in which B). the experiments were performed, neutrophils from women during the follicular phase were in vitro incubated with 3 .2. Expression of nNOS protein in neutrophils: 28 28 10 mol / l 17b-estradiol. 17b-Estradiol (10 mol / l) involvement of SP-1 and AP-1 transcription factors 28 As previously reported [12, 13] , 17b-estradiol (10 mol / l) induced nNOS expression in neutrophils derived from men (Fig. 5A) , an effect that was prevented by both 28 28 10 mol / l tamoxifen and 10 mol / l ICI 182780 (Fig.  5A) . The level of inhibition of nNOS expression achieved with ICI 182780 was higher than with tamoxifen (Fig. 5A ).
In the absence of 17b-estradiol, the level of nNOS protein expression was not statistically modified by any of the two estrogen autoregulates ER expression in human neutrophils ER antagonists (Fig. 5A) . During the ovulatory phase was the association observed between estrogen circulatory nNOS expression was higher than in the follicular phase levels and the level of ER expressed in neutrophils from (Fig. 5B) . Fig. 5C shown the specificity of the nNOS premenopausal women. Moreover, in neutrophils isolated antibody used.
from men, 17b-estradiol stimulated ER expression, an The nNOS promoter did not contain a canonical eseffect that was prevented by two different ER antagonists, trogen response element (ERE), but binding sites for tamoxifen and ICI 182780. Interestingly, at equimolar different transcription factors have been identified [19] .
concentrations, ICI 182780 seems to be more potent to 17b-Estradiol stimulated DNA binding activity of both inhibit 17-b estradiol-induced ER expression than tamoxSp-1 and AP-1 transcription factors in neutrophils derived ifen. McClelland et al. [33] have also reported a greater from men ( Fig. 6A and B) . The presence of mithramycin inhibition of estrogen-induced events by ICI 182780 than 26 26 A (10 mol / l) and curcumin (10 mol / l), two inhibitors by tamoxifen, which could be related to the known of Sp-1 and AP-1, respectively [31, 32] , prevented the agonistic / antagonistic effect of tamoxifen. In neutrophils 28 effect of 17b-estradiol (10 mol / l) on the DNA binding derived from men, 17b-estradiol increased the expression activity of Sp-1 and AP-1 (Fig. 6A and B ). An excess of of the ERa subtype but not the ERb subtype. The unlabelled Sp-1 and AP-1 probes prevented complex upregulation of ERa in 17b-estradiol-stimulated neutroformation by nuclear extracts from 17b-estradiol-incubated phils was prevented by ICI 182720. These results suggest neutrophils and labelled Sp-1 and AP-1, supporting bindthat estrogen modulate ERa subtype expression but not ing specificity ( Fig. 6A and B) .
ERb subtype expression in neutrophils from men. HowWe then analyzed whether Sp-1 and AP-1 are involved ever, in premenopausal women during the menstrual state in the upregulation of nNOS and ERa by 17b-estradiol. associated with high estrogen levels (ovulation), both ERa Western blot analysis showed that both mithramycin A and ERb were upregulated in the neutrophils. These results 26 26 (10 mol / l) and curcumin (10 mol / l) prevented the may suggest a different gender-dependent regulation of 28 expression of nNOS protein induced by 10 mol / l 17b-ERa and ERb in neutrophils from premenopausal women estradiol in neutrophils derived from men (Fig. 7A ). ERa and from men. It was further supported by the fact that in subtype expression induced by 17b-estradiol was also vitro incubation of neutrophils from women during the reduced by both mithramycin and curcumin (Fig. 7B) .
follicular phase with 17b-estradiol upregulated both ERa and ERb subtype expression. Unfortunately, there are no specific blockers of ERa and
. Discussion
ERb to establish the type of ER associated with nNOS expression. However, the experiments with neutrophils Neutrophils play a detrimental role in the setting of from men demonstrated that upregulation of nNOS exprescardiovascular diseases such as myocardial ischemia. In a sion was accompanied by an enhanced expression of the previous work, we have shown that upregulation of nNOS ERa subtype, suggesting the involvement of this ER protein expression by estrogen was involved in the reducsubtype. In this regard, a case has been reported of a young tion of the expression of CD11 / CD18 adhesive proteins man who has no functional ERa and has impaired brachial and the adhesiveness of these cells [12] . Moreover, 17b-endothelium-dependent relaxation supporting the imporestradiol-incubated neutrophils showed a greater ability to tance of ERa on the NO system [34] . Although nNOSprevent platelet activation [10] . However, the mechanism encoding genes were originally considered to be constituby which estrogen upregulated nNOS expression and the tive it has become evident that their expression is regulated ER subtype expressed in neutrophils remains to be estabby a variety of stimuli including estrogen [12, 35] . lished.
The mechanisms by which estrogen stimulated nNOS In the present study we have shown that neutrophils protein expression in neutrophils remains to be determined, from premenopausal women and healthy men expressed given that the 59-flanking region of nNOS gene does not ERa and ERb subtypes. However, whereas in precontain a canonical estrogen response element [19] . There menopausal women the expression of ERa and ERb was are two known mechanisms by which ER could activate upregulated during ovulation (high serum estrogen congene expression. In the best understood mode of action, or centration), and by in vitro incubation with 17b-estradiol classical pathway, the ER bind to a specific estrogen in neutrophils obtained during follicular phase (low serum response element within target genes. In the second mode estrogen concentration), 17b-estradiol only upregulated the of action, the ER utilizes unspecified protein-protein expression of the ERa subtype in neutrophils from men.
interactions to enhance the activity of heterologous tranThere are evidences demonstrating that estradiol induce scription of genes that contain binding sites for AP-1 and the expression of ER during the menstrual cycle in the Sp-1 such as the Jun / Fos complex and c-myc [20] [21] [22] . uterus of experimental animals and in different organs of
In our study, 17b-estradiol stimulated the DNA binding nonmammalian vertebrates, although less is known in activity of Sp-1 and AP-1 in neutrophils. Moreover, human cells [14] [15] [16] [17] [18] . In our study, the first suggestion that inhibition of DNA binding activity of Sp-1 and AP-1 arkedly reduced neutrophil nNOS expression induced by fellow of Fundacion Conchita Rabago de Jimenez Dıaz. 17b-estradiol. Interestingly, blockade of Sp-1 and AP-1
The authors thank Begona Larrea for secretarial assistance. transcription factors also reduced 17b-estradiol-induced overexpression of ERa in neutrophils from men, suggesting that these transcription factors are also involved in R eferences the autoregulation of ERa by estrogen. In this regard, Tang et al. [36] have identified a functionally important AP-1 us to determine whether SP-1 and AP-1 acts independently
